Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.
Epistemonikos ID: 384674a18bf3e9571dffbf722ea454e4094716d4
First added on: May 10, 2024